Chalcogen Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/254.07)
-
Publication number: 20120225118Abstract: Compositions and methods of making the same for improving the bioavailability of a substantially water-insoluble pharmacologically active agent are described. The composition includes a substantially water-insoluble pharmacologically active agent, and a substantially water-insoluble matrix forming material comprising enzyme digestible or bile soluble nutrients, wherein the substantially water-insoluble pharmacologically active agent is dispersed in a solid matrix and wherein said pharmacologically active agent in said matrix is substantially free of the original crystalline form.Type: ApplicationFiled: February 23, 2012Publication date: September 6, 2012Applicant: Latitude Pharmaceuticals IncorporatedInventors: Hailiang Chen, Andrew Xian Chen
-
Publication number: 20120225867Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 27, 2010Publication date: September 6, 2012Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, lisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
-
Publication number: 20120207751Abstract: The invention relates to a combination comprising compounds of formula (I) and one or more other antiproliferative compounds, hormones or radiation, pharmaceutical preparations comprising the combination thereof, and the application thereof in a process for the treatment of tumors.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicant: NOVARTIS AGInventors: Carlos Garcia-Echeverria, Frédéric Stauffer, Pascal Furet
-
Publication number: 20120207845Abstract: The invention relates to a method for treating disorders or diseases of a tight junction comprising delivering a pharmaceutical composition of nanoparticles to the tight junction, wherein the nanoparticles consist of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating said disorders or diseases of the tight junction of an animal subject.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Inventors: Hsing-Wen Sung, Kiran Sonaje, Ho-Ngoc Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Publication number: 20120208795Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: January 13, 2012Publication date: August 16, 2012Applicant: Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventor: Nicholas E. Goeders
-
Patent number: 8236806Abstract: The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.Type: GrantFiled: July 13, 2007Date of Patent: August 7, 2012Assignee: Korea Research Institute of Chemical TechnologyInventors: Jae Yang Kong, Woo-Kyu Park, Heeyeong Cho, Daeyoung Jeong, Gildon Choi, Hun Yeong Koh, Sang Hee Kim, Ae Nim Pae, Yong Seo Cho, Joo Hwan Cha, Hyunah Choo, Sang Eun Chae, Hee-Yoon Lee
-
Patent number: 8236791Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.Type: GrantFiled: August 10, 2006Date of Patent: August 7, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Anne Reba Bresnick, Sarah Claire Garrett
-
Publication number: 20120196873Abstract: The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compositions comprising sponge-like carrier matrices, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compositions.Type: ApplicationFiled: June 19, 2009Publication date: August 2, 2012Inventors: Marc Nolte, Jörg Mayer, Maria Gonzalez Ferreiro, Annette Assogba-Zandt, Volker Fehring, Lutz Kröhne, Andreas Voigt, Christoph Dunmann
-
Publication number: 20120178724Abstract: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Joseph Michael Sprafka, II, Jose Mauro Goulart-Brum
-
Publication number: 20120177712Abstract: This invention relates to a bipolar antimicrobial particle for use in laundry detergent compositions, fabric conditioners, personal care and cosmetic compositions and a process for making the same. In view of the foregoing, it is an object of the present invention to provide a stabile antimicrobial agent immobilised on a carrier particle. It is a further objective to provide an antimicrobial particle with improved retention to the fabric so that larger amounts of antimicrobial will be available even after rinsing. Surprisingly it has been found that antimicrobial molecules tagged by surface reaction onto naturally occurring asymmetric clay surfaces, act as an antimicrobial particle with improved retention properties with improved stability.Type: ApplicationFiled: August 30, 2010Publication date: July 12, 2012Inventors: Arpita Bhattacharya, Sudipta Ghosh Dastidar, Vidula Iyer, Suresh Sambamurthy Jayaraman, Maya Treesa Saji
-
Publication number: 20120178762Abstract: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.Type: ApplicationFiled: February 3, 2012Publication date: July 12, 2012Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Nancy Lee REDMAN-FUREY, Nicholas William GEARY, Tammy BAKER
-
Publication number: 20120172364Abstract: Rate-controlled particles, comprising compounds of the formula as a solid dispersion.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Inventors: Thomas Hantke, Bettina Rehbock, Jörg Rosenberg, Jörg Breitenbach
-
Publication number: 20120157396Abstract: Applicants claim the use of a pyrazine compound of formula I: or a salt thereof, for treating or preventing leishmaniases, and diseases and disorders caused by Trypanosoma cruzi or Trypanosoma brucei, and for inducing immunostimulation.Type: ApplicationFiled: November 21, 2011Publication date: June 21, 2012Applicants: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, UNITED STATES GOVERMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIR, CORNELL UNIVERSITYInventors: John T. WELCH, Susana MENDEZ, Michael H. CYNAMON
-
Publication number: 20120129844Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: ApplicationFiled: January 26, 2012Publication date: May 24, 2012Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
-
Publication number: 20120115881Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
-
Publication number: 20120114574Abstract: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions and evaporation of volatile solvents, the composition produces a film, which has web-like structures containing the active agent(s).Type: ApplicationFiled: August 1, 2011Publication date: May 10, 2012Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventor: Elka Touitou
-
Publication number: 20120114604Abstract: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Roger Tung, Gurudatt Chandorkar, Robert Perni
-
Publication number: 20120114600Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 3, 2011Publication date: May 10, 2012Applicant: THERAVANCE, INC.Inventors: Robert Murray McKINNELL, Daniel D. LONG, Lori Jean VAN ORDEN, Lan JIANG, Mandy LOO, Daisuke Roland SAITO, Shella ZIPFEL, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
-
Publication number: 20120101053Abstract: The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.Type: ApplicationFiled: June 16, 2010Publication date: April 26, 2012Inventors: Cameron Black, Christian Beaulieu
-
Publication number: 20120100124Abstract: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.Type: ApplicationFiled: June 25, 2010Publication date: April 26, 2012Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), AFFICHEMInventors: Philippe De Medina, Michaél Paillasse, Marc Poirot, Sandrine Silvente-Poirot
-
Publication number: 20120095006Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.Type: ApplicationFiled: December 16, 2011Publication date: April 19, 2012Inventors: Ghazwan Saleem Butrous, Timothy Michael Lukas, Ian Machin
-
Publication number: 20120095019Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.Type: ApplicationFiled: August 31, 2011Publication date: April 19, 2012Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
-
Patent number: 8148367Abstract: Disclosed are compounds, pharmaceutical compositions, kits, articles of manufacture, methods of using, and methods of preparing compounds having the formula: wherein the variables are as defined herein. The disclosed compounds are inhibitors of Renin.Type: GrantFiled: January 9, 2008Date of Patent: April 3, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Lily Kwok, Betty Lam, Zhe Li, Zhiyuan Zhang
-
Publication number: 20120077822Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.Type: ApplicationFiled: January 29, 2011Publication date: March 29, 2012Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
-
Publication number: 20120077767Abstract: Methods for identifying fungal infection, assays for identifying genomic and protein markers of fungal infection, and methods for diagnosing the fungal infection. In one aspect, the method of identifying fungal infection by proteomic assay involves measuring the protein levels of proteins listed in Table 2A in a peripheral blood cell sample and comparing the determined protein levels to standard protein levels. In another aspect, subjects identified as being infected with fungal infection are treated with anti-fungals.Type: ApplicationFiled: May 26, 2010Publication date: March 29, 2012Inventors: Aimee K. Zaas, Geoffrey S. Ginsburg, Joseph Lucas, Hamza Aziz, John R. Perfect
-
Publication number: 20120077823Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.Type: ApplicationFiled: January 29, 2011Publication date: March 29, 2012Inventors: Shalaby W. Shalaby, Georgios T. Hilas, Sheila Nagatomi
-
Publication number: 20120077824Abstract: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic surfactant/emulsifier in a concentration of from about 20% to about 50%, a co-surfactant in a concentration from about 10% to about 45% and a stabilizer in a concentration of from about 1% to about 15%.Type: ApplicationFiled: September 22, 2011Publication date: March 29, 2012Inventors: Dong Liang, Lei Wu, Mathew Kizhakkekara Joseph, Jyothy Anie John
-
Publication number: 20120071456Abstract: Hair treatment composition comprising a zinc-based antidandruff agent, a conazole fungicide and a cationic modified guar deposition polymer.Type: ApplicationFiled: April 12, 2010Publication date: March 22, 2012Inventors: Wanlin Chang, Amit Jayaswal, Zheng Rong Li, Busaraporn Samran
-
Publication number: 20120070384Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.Type: ApplicationFiled: June 21, 2011Publication date: March 22, 2012Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Greg DAVEY, Albert Zorko ABRAM
-
Publication number: 20120058199Abstract: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.Type: ApplicationFiled: February 19, 2010Publication date: March 8, 2012Applicant: BASF SEInventors: Andreas Buthe, Andreas Hafner, Franz Kaufmann, Babette Fiedler, Guido Meurer, Gordon Bradley
-
Publication number: 20120053139Abstract: The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.Type: ApplicationFiled: August 24, 2011Publication date: March 1, 2012Applicant: Ambrilia Biopharma Inc.Inventors: Jinzi Jason Wu, Brent Richard Stranix, Michael Ge, Guy Milot, Marco Petrella, Chandra J. Panchal
-
Publication number: 20120052130Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: April 12, 2010Publication date: March 1, 2012Inventors: Etzer Darout, Michael Paul DeNinno, Kentaro Futatsugi, Cristiano Ruch Werneck Guimaraes, Bruce Allen Lefker, Vincent Mascitti, Kim Francis McClure, Michael John Munchhof, Ralph Pelton Robinson, JR.
-
Publication number: 20120040995Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.Type: ApplicationFiled: February 9, 2010Publication date: February 16, 2012Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
-
Publication number: 20120035186Abstract: Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.Type: ApplicationFiled: April 13, 2010Publication date: February 9, 2012Inventors: Jason Shaun Burry, Richard Livesey Evans, Graham Andrew Turner
-
Publication number: 20120028920Abstract: A heterocyclic compound or a salt thereof represented by the formula (1): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: ApplicationFiled: October 11, 2011Publication date: February 2, 2012Inventors: Hiroshi YAMASHITA, Hideaki Kuroda, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Haruka Takahashi, Tae Fukushima, Satoshi Shimizu, Kazumi Kondo, Yohji Sakurai, Takeshi Kuroda, Shinichi Taira, Motohiro Itotani, Tatsuyoshi Tanaka
-
Publication number: 20120022021Abstract: The present invention relates to mixtures comprising a) a compound of the formula I in which X, m, Q and a are as defined in the description and b) one or more ethylene modulators (II) selected from the group consisting of: inhibitors of ethylene biosynthesis which inhibit the conversion of S-adenosyl-L-methionine into 1-aminocyclopropane-1-carboxylic acid (ACC), inhibitors of ethylene biosynthesis which block the conversion of ACC into ethylene, or inhibitors of ethylene action, and also to compositions comprising them and to their use for controlling harmful fungi.Type: ApplicationFiled: September 28, 2011Publication date: January 26, 2012Applicant: BASF SEInventors: Wilhelm RADEMACHER, John S. HARDEN, Dan E. WESTBERG, Joseph E. ZAWIERUCHA, Thomas J. HOLT, Hendrik YPEMA, Ted R. BARDINELLI, Albert C. EVERSON, Edson BEGLIOMINI
-
Publication number: 20120022079Abstract: The invention relates to a process for producing formulations of sparingly water-soluble substances, said sparingly soluble substances being present in amorphous embedded form in a copolymer, and said copolymer being obtained by free-radically initiated polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the sum of components i), ii) and iii) equals 100% by weight, which comprises embedding the sparingly soluble substance into the copolymer at temperatures above the melting point of the sparingly soluble substances.Type: ApplicationFiled: March 30, 2010Publication date: January 26, 2012Applicant: BASF SEInventors: Kathrin Meyer-Böehm, Rainer Dobrawa, Stefan Fischer, Karl Kolter
-
Publication number: 20120010161Abstract: The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R1, R2, R3, X1, X2, X3, X4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds as adjuvant for an anticancer or anti-infectious medicament.Type: ApplicationFiled: January 25, 2010Publication date: January 12, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON IInventor: Joelle Paris
-
Publication number: 20120003306Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
-
Patent number: 8084445Abstract: Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate.Type: GrantFiled: August 10, 2005Date of Patent: December 27, 2011Assignee: Schering-Plough Animal Health CorporationInventors: Abu S Huq, Allan J Weingarten, Robert D Simmons
-
Publication number: 20110311545Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).Type: ApplicationFiled: November 24, 2009Publication date: December 22, 2011Inventors: Amol Madhusudan Patwardhan, Kenneth Michael Hargreaves, Armen Norakovich Akopian
-
Publication number: 20110312931Abstract: The compounds of the present invention are represented by the following formula (I): wherein the substituents R1, R2, R3, R4, (R5)m, R6, A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.Type: ApplicationFiled: June 2, 2011Publication date: December 22, 2011Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Christopher L. CIOFFI, Mark A. WOLF, Peter R. GUZZO, Shuang LIU, Kashinath SADALAPURE, Visweswaran PARTHASARATHY, Jun-Ho MAENG
-
Publication number: 20110300104Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Inventors: Yao-Ling Qiu, Ce Wang, Hui Cao, Xiaowen Peng, Datong Tang, Yat Sun Or
-
Publication number: 20110301099Abstract: A method and composition that allows for the penetration of lipid insoluble medicaments through cell membranes using small S-Allyl-containing molecules with phospholipid permeable molecules as carrier molecules. S-Allyl-containing compounds can include alliin, allicin, Allium sativum extract and DMSO. Lipid insoluble medicaments can include 1% xylocaine, curcumin, acyclovir, valacyclovir, famciclovir, terbenafin, griseofulvin, clotrimazole, ketoconazole, clindamycin, neomycin, polysporin, bactricin, among others. The lipid insoluble medicaments are mixed with the phospholipid permeable molecules and painted on the skin using a swab or other suitable tool, thereby allowing for penetration of the medicament and providing relief from pain potentially caused by a subsequent injection. The composition can also be administered through an inhaler or directly into mucous membranes.Type: ApplicationFiled: June 4, 2010Publication date: December 8, 2011Inventor: Madalene Choon Ying Heng
-
Publication number: 20110287066Abstract: Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which the propellant is in the supercritical state, in stage b) heating of the laden polymer molding compound or melt is carried out under pressure at a temperature which lies in the range from ?40 to +60° C., preferably ?20 to +55° C., and especially preferably 0 to +50° C. around the glass transition temperature of the unladen (prior to loading) polymeric molding compound and in stage c) a depressurization of the polymeric molding compound or melt laden in stage a) and heated under pressure in stage b) is effected out with a depressurization rate in the range from 15,000 to 200,000 MPa/sec.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: BASF SEInventors: Jan Kurt Walter Sandler, Ingo Bellin, Dejan Djuric, Karl Kolter, Holger Ruckdäschel
-
Publication number: 20110281810Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.Type: ApplicationFiled: April 13, 2011Publication date: November 17, 2011Applicant: Cognis IP Management GmbHInventors: Kirsten Petersen, Bernd W. Müller, Thomas Rosen
-
Publication number: 20110274651Abstract: Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds.Type: ApplicationFiled: September 4, 2009Publication date: November 10, 2011Applicant: Emory UniversityInventors: Cory Acuff, Daniel Kalman
-
Publication number: 20110275558Abstract: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicant: Virginia Tech Intellectual Properties, Inc.Inventors: Josep BASSAGANYA-RIERA, Pinyi LU, Raquel HONTECILLAS
-
Publication number: 20110269768Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.Type: ApplicationFiled: July 14, 2011Publication date: November 3, 2011Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey
-
Publication number: 20110262517Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.Type: ApplicationFiled: April 7, 2008Publication date: October 27, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jun O. Liu, Curtis R. Chong, Jing Xu, Jun Lu, Shridhar Bhat